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The End TB Strategy approved by the World Health Assembly in 
May 2014 aims to end the global tuberculosis epidemic by 2035, 
with the ambitious targets of a 95% reduction of tuberculosis 
mortality, a 90% decline in tuberculosis incidence, and zero cat-
astrophic costs for tuberculosis-affected households [1]. Despite 
recent advances in the diagnosis and treatment for tuberculosis, 
overall progress in reducing the incidence of tuberculosis and 
tuberculosis-related deaths, as well as the burden and costs associ-
ated with tuberculosis in the most affected communities, has been 
constrained by the inadequate implementation and scale-up of 
existing tools to detect, treat, and prevent tuberculosis [2]. A sys-
tematic review of World Health Organization–recommended 
interventions for tuberculosis prevention and care has demon-
strated a lack of specific data on their effectiveness in real-world, 
programmatic settings [3]. This includes limited information on 
epidemiological impact and cost-effectiveness that are essential to 
inform decisions about scale up and the operationalization of evi-
dence-based tuberculosis guidelines [3]. In 2016, more than 10.4 
million new cases of tuberculosis were estimated to have occurred, 
with 6.1 million being reported to national surveillance systems, 
suggesting a failure in health systems to find, diagnose, and 
report approximately 4 million tuberculosis cases [2]. Country-
level analyses of available epidemiological, health systems, and 
health-seeking behavior data can provide useful insights into 
where exactly these losses are observed along the patient path-
way of tuberculosis care [4]. This approach allows for translating 
existing national- and subnational-level data into programmatic 
gaps that promote more favorable outcomes relevant to the care 
of tuberculosis patients, such as early case detection, reduced loss 
to follow-up of case patients before they start treatment, improved 
treatment outcomes, and decreased levels of mortality.
Articles published in this supplement illustrate how the anal-
ysis of patient pathways to tuberculosis care can identify the 
programmatic gaps in the implementation of key interventions 
for tuberculosis detection, care, and prevention. The importance 
of community referral networks for more effective detection of 
drug-sensitive tuberculosis in Ethiopia and the Philippines is 
highlighted [5, 6]. The role of bacteriological confirmation and 
notification of cases in Pakistan and Indonesia, where initial 
care-seeking behavior brings most individuals to the private sec-
tor, is identified as a key area to address [7, 8]. These analyses 
and their results highlight the need to integrate patient-centred 
approaches with the interpretation, monitoring, and evaluation 
of tuberculosis surveillance and, where necessary, survey data 
in national tuberculosis policy decision making. To reach the 
ambitious targets of the End TB Strategy, strengthened surveil-
lance systems, patient-centred analyses, and intensified imple-
mentation research are essential to operationalize and optimize 
existing and novel interventions for tuberculosis prevention and 
high-quality care that address programmatic gaps and barriers 
faced by patients.
Improving the patient pathway of tuberculosis care requires 
a multifaceted approach that starts with the gap identification 
and description. This can be achieved through the analysis and 
use of available quality surveillance and survey data, both at 
national and subnational levels, and the optimal implementation 
of a package of complementary tools to synthesize and interpret 
these data for use in informing programmatic local action. This 
package of tools includes, but is not limited to, tuberculosis pro-
gram reviews, tuberculosis epidemiological and impact reviews, 
diagnostic and patient pathway to tuberculosis care analyses, and 
mathematical modeling projections for the allocative efficiency 
of interventions and the expected impact they can have on the 
tuberculosis burden. Findings from this package of tools need to 
be translated into solutions for addressing barriers to reaching 
care, explain why these gaps exist, and demonstrate how to close 
them such as through implementation research, for example. 
By providing a framework (Figure  1) to national stakeholders 
that starts from the identification and description of gaps and 
then translates gaps into activities and targeted interventions, we 
can improve program performance and healthcare delivery by 
restructuring health systems and overcoming barriers to care in 
a context-specific and evidence-based manner.
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Tuberculosis epidemiological reviews offer a systematic 
description and assessment of the surveillance systems in place 
to monitor tuberculosis cases and deaths, including the compila-
tion of national and subnational tuberculosis surveillance data to 
study and interpret time trends, as well as collate data on deter-
minants of tuberculosis [2]. These data often lead to the identi-
fication of corrective actions required to strengthen surveillance 
systems and improve the direct measurement of the tubercu-
losis burden. Patient and diagnostic pathway analyses identify 
and describe the gaps and barriers all along the cascade of care, 
mapping epidemiological data to the patient experience [9]. The 
Screen TB tool offers insights into target prioritization and strat-
egy selection for tuberculosis screening among groups that are 
either at high risk of developing tuberculosis disease and/or are 
underserved and vulnerable [10]. Finally, mathematical model-
ing projections allow an investigation into the impact that avail-
able interventions could have on the tuberculosis burden [11].
The current global status of available key surveillance and sur-
vey tuberculosis data is shown in Figure 2. The best approach to 
estimating tuberculosis incidence, a key indicator of the End TB 
Strategy, is through robust routine surveillance of tuberculosis 
case notifications. In settings where universal health coverage is 
available and efforts are made to understand and quantify the gaps 
of the surveillance system, notifications are considered a proxy 
for incidence (Figure 2A) [2]. The major reasons why cases are 
missing from routine surveillance of notification data include lab-
oratory errors, lack of notification of cases by public and private 
providers, failure of people accessing health services with sug-
gestive symptoms to be identified as potential tuberculosis cases, 
and lack of access to health services [2]. Tuberculosis mortality, 
another key indicator of the End TB Strategy, is best captured 
from vital registration systems with high coverage and accurate 
recording of cause of death according to the latest revision of the 
International Classification of Diseases (Figure 2B) [2]. In addi-
tion to routine surveillance, special studies and surveys carried 
out on a post hoc basis also provide empirical measurements of 
the tuberculosis burden. A  true revolution in the availability of 
robust data on tuberculosis burden has been observed since 2009 
in the form of national tuberculosis prevalence surveys among 
the general population, with 23 countries implementing a survey 
(Figure 2C) [2]. Meanwhile, the Global Project on Anti-TB Drug 
Resistance Surveillance has been systematically collecting and 
analyzing data on drug resistance worldwide since the mid-1990s 
(Figure 2D) [2]. More recently, new types of tuberculosis studies 
are also being implemented and are providing important data: 
tuberculosis inventory studies that measure tuberculosis under-
reporting, and cost surveys that measure the percentage of tuber-
culosis cases and their households that face catastrophic costs as a 
result of tuberculosis disease [2].
As described in the articles in this supplement, leveraging 
these rich and varied data sources and synthesizing them into 
a patient-centred analysis of health system performance can 
clearly identify and describe specific programmatic gaps in 
tuberculosis care at both national and subnational levels. What 
next then? The usefulness of this gap analysis is only as strong 
as its ability to direct us to solutions that ultimately improve 
tuberculosis patient outcomes. Implementation research (IR) 
can provide a necessary, systematic approach to explaining why 
these gaps exist, addressing patient and provider barriers to 
care, and using systematic frameworks to design evidence-based 
approaches on how to overcome programmatic obstacles.
Implementation research is designed to find ways to close 
evidence-practice gaps—gaps between what is recommended 
and what actually occurs in routine tuberculosis practice. 
By understanding the difference between current practice in 
tuberculosis care and the ideal in terms of underlying behav-
ioral and structural contexts, and the outcome gap, the impact 
on tuberculosis and overall health outcomes as a result of 
implementation of evidence-based care, IR seeks to identify 
and make concrete targets for improved implementation strat-
egies. An approach rooted in IR presents a step-wise model for 
programs and other key stakeholders in planning, designing, 
and evaluating intervention deployment [12]. In the past, the 
majority of evidence-based healthcare interventions, includ-
ing tuberculosis care, have been adopted in an ad hoc man-
ner, with little basis and evidence on how to optimally scale 
up. Implementation research counters this tendency by pro-
viding a framework for engaging stakeholders in planning, 
considering both structural and strategic contexts that could 
affect program implementation, conducting formative research 
necessary to identify the behavior change required to improve 
implementation, designing interventions that target those 
behaviors, and setting up robust monitoring and evaluation 
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Figure 1. Framework for use of data and implementation of tools to identify and 
address gaps in tuberculosis prevention and care and contribute toward reaching 
the targets of the End TB Strategy.
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systems that provide evidence of both implementation strategy 
uptake and intervention effect [13]. The result is that programs 
and stakeholders have a clearer sense of what worked, what did 
not work, and why.
The benefits of combining available gap identification tools 
with IR are potentially game changing for tuberculosis control. 
Findings from the optimal implementation of the available 
package of tools allow national tuberculosis programs to develop 
national and subnational strategic plans (NSPs) for tuberculosis 
that take into account the context-specific epidemiology, health 
system, and tuberculosis determinants. These NSPs can then be 
leveraged to attract support from both domestic and interna-
tional funding sources, either as part of national research and 
program funds or through proposals to funding institutions. 
A recent study indicates that country programs are hesitant to 
request such funds, even when the opportunity exists [14]. This 
is likely caused by a lack of a systematic approach to synthe-
sizing context-specific data into meaningful action with patient 
and public health impact. By using this package of tools with 
IR, one can provide a framework to programs and stakehold-
ers that identifies gaps, translates gaps into research questions, 
provides a framework to design pilot projects to answer these 
questions, and evaluates the impact of an implementation strat-
egy to obtain meaningful context-specific data. This approach is 
expected to provide the basis for rapid and appropriate scale-up, 
implementation, and dissemination of new tools and interven-
tions, which are critical for achieving short- (2020) and medi-
um-term (2025) End TB Strategy targets, better tuberculosis 
care delivery, less suffering, and reduced transmission.
The tuberculosis world is currently witnessing a real revolu-
tion in the availability of surveillance and survey data at both 
national and subnational levels and a package of complemen-
tary tools that can harness the power of those data and translate 
them into policy, planning, advocacy, and programmatic action. 
Optimal implementation of these tools provides a real opportu-
nity for progress toward reaching the ambitious targets of the 
End TB Strategy, one we cannot afford to miss.
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Figure 2. Current methods to monitor levels of, and trends in, tuberculosis incidence (A), tuberculosis mortality in HIV-negative people estimated using measurements 
from vital registration systems and/or a mortality survey (B), status of empirical measurements of tuberculosis burden with national prevalence surveys (C), and surveillance 
of antituberculosis drug resistance (D).
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